A. Carta

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

A. Rossi, D. Galetta, S. Novello, 2019, Lung cancer.

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma

A. Cossu, G. Palmieri, V. Doneddu, 2019, BMC Pulmonary Medicine.

Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma

A. Cossu, G. Palmieri, G. Sotgiu, 2015, Molecular medicine reports.

Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study

A. Cossu, G. Palmieri, V. Doneddu, 2022, BMC Pulmonary Medicine.

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

D. Galetta, R. Chiari, G. Tonini, 2018, Future oncology.

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology

Vito Barbieri, Paola Mazzanti, Claudia Yvonne Finocchiaro, 2019, Translational Cancer Research.

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.

M. Tiseo, A. Delmonte, S. Pilotto, 2023, Lung cancer.